Glenmark Pharmaceuticals Ltd said its Swiss arm has entered into an exclusive licensing agreement with Lotus International Pte Ltd for commercialising its innovative nasal spray Ryaltris in Singapore, Hong Kong and Vietnam.

• Shyam Metalics Slips Even as Q1 Volumes Surge
• Oswal Pumps, Shakti Pumps Rally on Solar Order Wins
• Glenmark, Granules Rally on US Drug Approvals
• Key Factors Behind Today’s Market Rally
• HDFC Bank Shares Climb 3% on Strong Q1 Update

Under the agreement signed between Glenmark Specialty SA and the wholly-owned subsidiary of Lotus Pharmaceutical Co, Ltd (Lotus), Glenmark will be responsible for the manufacturing and supply of Ryaltris.

On the other hand Lotus will be responsible for its commercialization subject to receipt of regulatory approvals, in these markets, the company said in a statement.